

## CORRIGENDUM

DOI: 10.3892/ol.2015.4039

### **Synthesis and positron emission tomography evaluation of 18F-Glu-Urea-Lys, a prostate-specific membrane antigen-based imaging agent for prostate cancer**

WEIWEI FAN, ZHIWEI ZHANG, ZHENG ZHU, DEYONG YANG, XIAOCHI CHEN, JIANBO WANG, FENG CHEN and XISHUANG SONG

Oncol Lett 10: 2299-2302, 2015; DOI: 10.3892/ol.2015.3625

Following the publication of this article, it came to our attention the fact that the title compound in our paper, 2-{3-[1-carboxy-5-(4-[18F]fluoro-benzoylamino)-pentyl]-ureido pentanedioic acid (18F-Glu-Urea-Lys; [18F]3), had been independently synthesized and evaluated seven years previously by another group, and the structure, its synthesis and its *in vivo* biological evaluation were published in the following paper:

Chen Y, Foss CA, Byun Y, Nimmagadda S, Pullambhatla M, Fox JJ, Castanares M, Lupold SE, Babich JW, Mease RC and Pomper MG: Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem 51: 7933-7943, 2008.

We deeply regret that our article did not cite the above paper.